View Older Stories View More Recent Stories

Mar 23, 2022 09:01AM Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
Feb 24, 2022 04:01PM Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 23, 2022 04:01PM Personalis to Present at the Cowen 42nd Annual Health Care Conference
Feb 15, 2022 08:08AM Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
Feb 10, 2022 04:01PM Personalis to Announce Fourth Quarter and Full-Year Financial Results
Feb 1, 2022 04:01PM Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 6, 2022 04:01PM Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Dec 28, 2021 04:01PM Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
Dec 16, 2021 08:45AM Personalis, Inc. (PSNL) Launches NeXT Personal, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
Dec 16, 2021 08:45AM Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
Nov 18, 2021 04:26PM Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
Nov 12, 2021 09:03AM Personalis Named to Inc.'s 2021 Best-Led Companies List
Nov 11, 2021 04:05PM Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Nov 4, 2021 07:00AM Personalis Reports Third Quarter 2021 Financial Results
Nov 2, 2021 07:01PM Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
Oct 26, 2021 05:45PM Personalis (PSNL) Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
Oct 26, 2021 05:45PM Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
Oct 26, 2021 04:25PM Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Oct 21, 2021 09:00AM Personalis to Announce Third Quarter Financial Results on November 4, 2021
Oct 13, 2021 09:03AM Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement
Oct 12, 2021 09:10AM Personalis, Inc. (PSNL) Collaborates with Mayo Clinic to Expand Cancer Genomic Testing
Oct 12, 2021 09:10AM Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing
Sep 18, 2021 10:50PM Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth
Aug 26, 2021 04:01PM Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
Aug 25, 2021 04:01PM Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development
Aug 4, 2021 04:01PM Personalis Reports Second Quarter 2021 Financial Results
Aug 3, 2021 04:01PM Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Aug 2, 2021 04:39PM Personalis, Inc. (PSNL) Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
Aug 2, 2021 04:05PM Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
Jul 21, 2021 04:01PM Personalis to Announce Second Quarter Financial Results on August 4, 2021
Jun 22, 2021 09:01AM Personalis Announces NeXT Level Biomarkers Symposium
Jun 2, 2021 04:03PM Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
May 17, 2021 08:01AM Personalis, Inc. to Present at Biomarkers Week Online 2021
May 5, 2021 04:01PM Personalis Reports First Quarter 2021 Financial Results
Apr 8, 2021 04:07PM Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®
Mar 29, 2021 04:03PM Personalis Announces Collaboration with MapKure to Use Personalis’ NeXT Platform™ for Clinical Trials and Companion Diagnostic Development
Mar 8, 2021 05:00PM Personalis Announces Changes to its Board of Directors
Feb 25, 2021 04:01PM Personalis Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 17, 2021 09:01AM Natera and Personalis Partner for Personalized Monitoring in Oncology
Feb 17, 2021 09:00AM Natera and Personalis Partner for Personalized Monitoring in Oncology
Feb 8, 2021 05:13PM Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
Jan 11, 2021 04:01PM Personalis Reports Preliminary Fourth Quarter 2020 Revenue
Dec 28, 2020 04:01PM Personalis to Present at the 23rd Annual Needham Virtual Growth Conference
Dec 17, 2020 09:09AM Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
Dec 17, 2020 09:07AM Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Dec 9, 2020 04:07PM Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
Nov 18, 2020 08:00AM Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
Nov 16, 2020 09:00AM Personalis® to Present at the AMP Annual Meeting 2020
Nov 9, 2020 04:12PM Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Nov 5, 2020 04:01PM Personalis Reports Third Quarter 2020 Financial Results
View More Recent Stories View Older Stories